References
- Sachs GS, Lafer B, Stoll AL, Banov M, Thibault AB, Tohen M, Rosenbaum JF. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994; 55: 391–393
- Stoudemire A. New antidepressant drugs and the treatment of depression in the medically ill patient. Psychiatr Clin North Am 1996; 19: 495–514
- Nunes EV, McGrath PJ, Quitkin FM. Treating anxiety in patients with alcoholism. J Clin Psychiatry 1995; 56: 3–9
- Belson MG, Kelley TR. Bupropion exposures: Clinical manifestations and medical outcome. J Emerg Med 2002; 23: 223–30
- Sheperd G, Velez LI, Keyes DC. Intentional bupropion overdoses. J Emerg Med 2004; 27: 147–51
- Davidson J. Seizures and bupropion : a review. J Clin Psychiatry 1989; 50: 256–261
- Johnston JA, Lineberry CG, Ascher JA, Davidson J, Khayrallah MA, Feighner JP, Stark P. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991; 52: 450–456
- Balit CR, Lynch CN, Isbister GK. Bupropion poisoning: A case series. Med J Aust 2003; 178: 61–63
- Spiller HA, Ramoska EA, Krenzelok EP, Sheen SR, Bory DJ, Villalobos D, Muir S, Jones-Easom L. Bupropion overdose: A 3-year multicenter retrospective analysis. Am J Emerg Med 1994; 12: 43–45
- Biswas AK, Zabrocki LA, Mayes KL, Morris-Kukoski CL. Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. J Toxicol Clin Toxicol 2003; 41: 101–104
- Curry SC, Kashani JS, Lo Vecchio F, Holubek W. Intraventricular conduction delay after bupropion overdose. J Emerg Med 2005; 29: 299–305
- Isbister GK, Balit CR. Bupropion overdose: QTc prolongation and its clinical significance. Ann Pharmacother 2003; 37: 999–1002
- Dutreika D, Zed PJ. Cardiotoxicity following bupropion overdose. Ann Pharmacother 2002; 36: 1791–1795
- Paris PA, Saucier JR. ECG conduction delaysassociated with massive bupropion overdose. J Toxicol Clin Toxicol 1998; 36: 595–598
- Jepsen F, Matthews J, Andrews FJ. Sustained release bupropion overdose: An important cause of prolonged symptoms after overdose. Emerg Med J 2003; 20: 560–561
- Johnston JA, Ascher J, Leadbetter R, Schmith VD, Patel DK, Durcan M, Bentley B. Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation. Drugs 2002; 62(suppl 2)11–24
- Van Wyck Fleet J, Mnberg PJ, Miller LL, Harto-Truax N, Sato T, Fleck RJ, Stern WC, Cato AE. Overview of clinically significant adverse reactions to bupropion. J Clin Psychiatry 1983; 44: 191–196
- Preskorn SH, Othmer SC. Evaluation of bupropion hydrochloride: The first of a new class of atypical antidepressants. Pharmacotherapy 1984; 4: 20–34
- Ferris RM, Beaman OJ. Bupropion: A new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic beta-adrenergic, serotoninergic (5-HT2), alpha 2-adrenergic, imipramine and dopaminergic receptors in brain. Neuropharmacology 1983; 22: 1257–1267
- Ferris RM, Cooper BR, Maxwell RA. Studies of bupropion's mechanism of antidepressant activity. J Clin Psychiatry 1983; 44: 74–78
- Harris CR, Gualtieri J, Stark G. Fatal bupropion overdose. J Toxicol Clin Toxicol 1997; 35: 321–324
- Trojak B, Pinoit JM, Disson-Dautriche A, Bonin B, Giusselmann. QT prolongation and second-generation antipsychotics: overdose and therapeutic dosage. Therapie 2004; 59: 558–61
- Theisen FM, Grabarkiewicz J, Fegbeutel C, Hubner A, Mehler-Wex C, Remschmidt H. Olanzapine overdose in children and adolescents: Two case reports and a review of the literature. J Child Adolesc Psychopharmacol 2005; 15: 986–95